Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know

Company Performance - Viking Therapeutics, Inc. (VKTX) experienced a daily increase of +1.39% to $32.07, outperforming the S&P 500's gain of 0.54% [1] - Prior to the latest trading session, the company's shares had risen by 20.36%, contrasting with the Medical sector's decline of 2.12% and the S&P 500's increase of 4.2% [1] Earnings Forecast - The upcoming earnings release is anticipated to show an EPS of -$0.44, reflecting a 120% decline compared to the same quarter last year [2] - For the full year, the Zacks Consensus Estimates predict an EPS of -$1.86 and revenue of $25 million, indicating changes of -84.16% and 0% respectively from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Viking Therapeutics should be monitored, as they often indicate short-term business trends [3] - Positive estimate revisions are viewed as a sign of optimism regarding the business outlook [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Currently, Viking Therapeutics holds a Zacks Rank of 3 (Hold), with no changes in the consensus EPS projection over the past 30 days [5] Industry Overview - The Medical - Biomedical and Genetics industry, which includes Viking Therapeutics, ranks in the top 34% of over 250 industries according to the Zacks Industry Rank [6] - The Zacks Industry Rank measures the strength of individual industry groups based on the average Zacks Rank of stocks within those groups [6]